Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can the addition of bevacizumab to IFL chemotherapy improve outcome in colorectal cancer?

Nature Clinical Practice Gastroenterology & Hepatology volume 1, pages 72–73 (2004)Cite this article

boxed-textHurwitz H et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342

Bevacizumab can be added to standard IFL chemotherapy for metastatic CRC, with an improvement in overall survival and an acceptable safety profile

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cunningham D et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 1337–1345

    Article  Google Scholar 

  2. Hecht JR et al. (2004) ABX-EGF monotherapy in patients with metastatic colorerectal cancer: an updated analysis. Proc ASCO 23: 248, a3511

    Google Scholar 

  3. Rougier Ph et al. (2004) Cetuximab+FOLFIRI as first line treatment for metastatic colorectal cancer. Proc ASCO 23: 248, a3513

    Google Scholar 

  4. Kabbinavar F et al. (2004) Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer in subjects who are not suitable candidates for first-line CPT-11. Proc ASCO 23: 249, a3516

    Google Scholar 

  5. Willett C et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145–147

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Minal Chande, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Medicine and Head of the Digestive Oncology Unit at the University Hospital Gasthuisberg, Leuven, Belgium

    Eric Van Cutsem

Authors
  1. Eric Van Cutsem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric Van Cutsem.

Glossary

ORAL FLUOROPYRIMIDINES

5-fluorouracil prodrugs, including capecitabine and UFT (uracil plus tegafur)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Van Cutsem, E. Can the addition of bevacizumab to IFL chemotherapy improve outcome in colorectal cancer?. Nat Rev Gastroenterol Hepatol 1, 72–73 (2004). https://doi.org/10.1038/ncpgasthep0051

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0051

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing